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Background: Human plasma, representing the most complete record of the individual phenotype, is an appealing
sample for proteomics analysis in clinical applications. Up to today, the major obstacle in a proteomics study of
plasma is the large dynamic range of protein concentration and the efforts of many researchers focused on the
resolution of this important drawback.
Findings: In this study, proteins from pooled plasma samples were fractionated according to their chemical
characteristics on a home-designed SPE automated platform. The resulting fractions were digested and further
resolved by reversed-phase liquid chromatography coupled with MALDI TOF/TOF mass spectrometry. A total of
712 proteins were successfully identified until a concentration level of ng/mL. Pearson correlation coefficient was
used to test reproducibility.
Conclusions: Our multidimensional fractionation approach reduced the analysis time (2 days are enough to
process 16 plasma samples filling a 96-well plate) over the conventional gel-electrophoresis or multi-LC column
based methods. The robotic processing, avoiding contaminants or lack of sample handling skill, promises highly
reproducible specimen analyses (more than 85% Pearson correlation). The automated platform here presented is
flexible and easily modulated changing fractioning elements or detectors.
Keywords: Human plasma, Proteomics, Automated platform, LC-MALDI, High-throughput analysisFinding
Background
The human blood plasma is the most complex human
derived proteome, containing also other tissue proteomes
as subsets [1]. Plasma has always been attractive because,
besides its easy and safe availability, it represents a
complete record of the individual physiological state. In
fact, plasma proteome modulations (in terms of concen-
trations and/or post-translational modifications) reflect
biological responses to pathological stimuli and generic
homeostasis changes [2]. As a consequence, highly spe-
cific biomarkers can be exploited to monitor therapeutic
response and their discovery can revolutionize early dis-
ease diagnosis and clinical proteomics. On the other
hand, plasma/serum is the most difficult protein-* Correspondence: lorenzo.citti@ifc.cnr.it
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reproduction in any medium, provided the orcontaining sample to be characterized mainly due to its
dynamic range of concentrations. In addition, clinical
proteomics studies are to be systematically conducted
and accomplished on large-scale populations in order to
obtain a statistical validation. Consequently in this field,
sensitivity, reproducibility and sample throughput are ne-
cessary and most important conditions in pre-analytical
and analytical steps [3,4].
Another big issue arises from the fact that plasma pro-
teins range from serum albumin at the higher abun-
dance level (35–50*109 pg/ml) to interleukin-6 at the
lower level (0–5 pg/ml) [1]. In proteomic studies, it is
crucial to reduce such an enormous concentration gap
by removing or depleting the most represented species,
which notoriously mask other proteins. This task is gen-
erally faced with immune-affinity techniques that exploit
specific antibodies or with cut-off size exclusion meth-
ods that ensure a higher reproducibility [5-8].l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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standardize pre-analytical treatment of specimens since
blood proteome profile was demonstrated to change
according to the nature of anti-coagulant (EDTA, citrate,
heparin), centrifugation speed and others [9,10].
Reproducibility together with limited sensitivity are
critical limitations also for two dimensional electro-
phoresis (2DE) which is the widest and most trad-
itional proteome separation method. Though the
differential in-gel electrophoresis (DIGE) technique,
introduced by Amersham Biosciences-Inc., is aimed
at improving reproducibility, the limited applicability
of this technology for large-scale samples remains
[5,11,12]. More recently, different proteomics strat-
egies, that use multidimensional LC columns coupled
with MS/MS analysis, have been developed [13].
These techniques are very sensitive but also expen-
sive and time consuming, especially if applied to high
complex mixtures [14-16]. For a better compromise,
other emerging methods for protein fractionation em-
ploy solid phase extraction (SPE) techniques [17-20].
All these methods are suitable for different mass
spectrometry strategies including ESI, SELDI and
MALDI [21-23]. Protein profiling using SELDI-TOF-
MS has gained over the past few years an increasing
interest. SELDI-TOF-MS provides a simple, low-
resolution pattern generated from proteins retained
on a specific chromatographic surface. Advantages of
SELDI are its ability to provide high-throughput and
rapid protein expression profiles from complex mix-
tures with minimal requirements for purification and
separation of proteins prior to detection [24]. Never-
theless, SELDI-TOF-MS has some limitations in a
routine identification of biomarkers. Additionally, the
low resolution, and hence mass accuracy, coupled
with the inability to do MS/MS, unlike MALDI-TOF-
TOF technology, prevents reliable identification based
on conventional bioinformatic searching. Moreover,
even if successful at discovering proteins in the low
molecular-weight range, it has not yet demonstrated
to be consistently successful in studying high mo-
lecular weight (HMW) proteins. The SELDI-TOF-MS
approach, respect to ESI interface, scrambles to iden-
tify hundreds or thousands of proteins in a single
analysis [25].
In this paper, a SPE-LC-MS workflow for simultaneous
processing of complex protein mixture was presented.
This method has been applied on Na-EDTA treated
plasma specimens adopting a molecular size cut-off pre-
processing [26,27] in order to deplete HMW proteins.
Multidimensional liquid chromatography (SPE-type)
automated technology has been applied to reduce sam-
ple complexity. Following trypsin digestion, peptide
samples were fractionated by C18 nano-HPLCchromatography and analysed by MALDI –TOF-TOF
mass spectrometry.
The majority of the processing steps have been auto-
matically performed by a robotic station thus preventing
sample handling errors.
Selectivity and reproducibility are thoroughly investi-
gated and assessed with mass spectral data.
Results and discussion
Experimental strategy
Sensitivity, selectivity, reproducibility are the main
hurdles in a clinical proteomics study of blood
plasma and in order to jump over them a reasoned
experimental workflow was designed. Four technical
replicates of plasma pooled from healthy volunteers
were analysed (Figure 1).
In a first step the most abundant proteins were
depleted in order to reduce the dynamic concentration
gap. A 30 kDa molecular size membrane cut-off was used
to remove HMW proteins [26,27]. This method, although
inducing an arbitrary threshold, it is demonstrated to
ensure a high reproducibility [28,29], necessary condi-
tion for high throughput applications in comparative
proteomics analyses (Additional file 1: Figure S1, S2,
S3). No significant levels of proteins larger than 50-
60 KDa were present in the eluted fraction and re-
flector mode analysis in the mass range 400-4000
confirmed a significant increase in detection level
and an increase of signals which are typically hidden
without cut-off. The considerable amount of larger
than 60 KDa proteins identified by our method is
quite surprising but it could be due to active frag-
mentation by endogenous proteases in tissues and
blood and not to an artefact of the plasma collection
or sample preparation. This is a critical aspect that
should be taken into consideration in future com-
parative analyses between physiological or patho-
logical states if proteome and/or degradome profiles
of samples need to be compared.
As a second step of this strategy, we applied and
patented a non-conventional automatic, robotic method
called parallel Multi Dimensional-Liquid Chromatog-
raphy (pMD-LC) (patent n° PCT/WO2010/035129 A2).
According to this method, the four cut-off selected frac-
tions were simultaneously processed by SPE on a mul-
tiple array device containing three distinctive stationary
phases (anion and cation phase and lipophilic-phase
chromatography) with different binding properties able
to trap acid, basic and lipophilic proteins. The auto-
mated sample processing was performed with a Liquid
Handler BiomekW NXP workstation (Beckman Coulter)
and the 96-well plate containing stationary phases was
in-house designed and optimized (Additional file 2).
Acid and basic fractions were collected on the basis of
Figure 1 Workflow overview. Eight plasma samples from healthy volunteers were collected into a pool to obtain four technical replicates. After
cut-off, each replicate was processed by SPE on a robotic device containing three different resins: anionic, cationic and liphophilic. The 24
obtained samples were further fractioned by nanoHPLC-MALDI-TOF-TOF analysis.
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ered according to polarity changes of the flushed so-
lution. Protein buffers (mobile phases) were carefully
determined and standardized in order to collect frac-
tions in a as small as possible volume. After protein
precipitation, all collected protein groups were sub-
jected to a third step to automatically exchange the
buffer in order to reduce, alkylate and digest the
samples. In the last step, plate containing peptide
mixtures was moved to HPLC-autosampler and each
sample was loaded on a C18 nano-HPLC column. A
good resolution of peaks and a convenient analysis
time were obtained using a 30 min H2O/TFA/ACN
linear elution gradient and each run was collected in
125 final MALDI spots (Figure 2).
Collected spots were subjected to MS and automatic
MS/MS analysis to provide accurate protein identifica-
tion (Additional file 3: Table S1, Additional file 4: Table
S2, Additional file 5: Table S3).
Comparison with other laboratories
In brief, 5612 peptides matching for more than 596 non
redundant proteins were identified (Additional file 3:Table S1, Additional file 4: Table S2, Additional file 5:
Table S3). The majority of the proteins were covered by
at least 3 peptides (Table 1) as demonstrated by the
mean ratio of 3.5 and in fact, only less than 5% of pro-
teins were identified by a single peptide. Table 1 sum-
marizes the obtained results.
Abundant proteins as well as low represented proteins,
such as coagulation factor VIII (normal plasma concen-
tration is estimated at about 1 ng/ml), were resolved into
6 order of magnitude of the dynamic concentration
range.
As a check of consistency, a comparative analysis of
the literature data was accomplished and it evidences
that only 30% of proteins in our maps are also identified
by Liu and other HUPO laboratories [11,30] (Additional
file 1: Table S4, S5).
The low overlapping among different laboratories is
due to peculiarities of the plasma samples that is a mix-
ture of different sets of proteins whose assortment
depends on individual instantaneous physiological state.
The fact that with our approach many identified compo-
nents appear to be unique demonstrates that different
fractionation strategies may disclose distinctive windows
Figure 2 Steps from cut-off to MALDI analysis. Photos show the device used to perform the entire sample process.
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discussed by Liu X et al [30].Selectivity of the methodology
An efficient protein fractionation in sub-families
allows a satisfactory protein identification and minimal
overlapping.
A total of 596 non-redundant proteins were identified
with of only 14 overlapping proteins (2.3%). In particu-
lar, the lipophilic fraction shares few proteins with the
acid and basic fractions, i.e. 4.5% and 5.7%. A bit
higher overlapping of 10% was observed between acidTable 1 LC-MALDI-TOF-TOF results












Anionic 125 7100 888 2700
Cationic 125 5832 729 1432
Lipophilic 125 6554 819 1480
a) number of total MS spectra/workflow; b) Peptide counts are based on non- redu
the same sample; c) Mean ± SD of identified proteins in four and three technical re
proteins; d) Efficiency is determined dividing the number of identified peptides perand basic fractions (Additional file 1: Figure S4 and
Tables S6–S9).
The low level of protein recurrences among the differ-
ent sub-sets proves the separation efficiency of solid
states and confirms the advantages of the SPE protein
fractionation to the classical LC strategies.
The majority of the recovered proteins (172 proteins
in anion-exchange and 106 proteins in cation-exchange)
displays, as expected, acid and basic pI respectively,
this highlighting the chemical specificity of the resins
(Additional file 1: Figure S6). pIs are calculated on the na-
tive, unmodified proteins while the real pI of the identified
















1305 163 ± 87.6 (326) 38% 3.8 ± 4.3 15 (4,6%)
718 94 ± 39.6 (188) 26% 3.9 ± 4.4 11 (1,5%)
691 99 ± 5.6 (198) 23% 4.0 ± 4.2 9 (1,3%)
ndant identifications in technical replicates and/or in redundant acquisitions of
plicates for SPE-LC-MS/MS analysis and in brackets number of total identified
MS/MS spectra.
Boccardi et al. BMC Research Notes 2012, 5:612 Page 5 of 9
http://www.biomedcentral.com/1756-0500/5/612Additionally the binding charge of the protein to the resin
can depend on the chemical characteristic of exposed
amino acid residues more than pI. This may explain the in-
complete selectivity, based on protein pIs of the ion-
exchange resins.
Reproducibility within single workflow
In order to perform comparative analyses reproducibility
is mandatory.
Sample pools have been used to avoid individual bio-
logical variability and thus to assess reproducibility.
UV-profiles reproducibility was checked by a prelimi-
nary graphical comparison of retention times and peak
intensities on over-layered chromatograms.
For MALDI analysis, shot number and spot coverage
are critical parameters to obtain reproducible signal in-
tensity. To overcome the problem of MS signal variations
due to heterogeneous sample-matrix co-crystallization,
an adequate laser number of shots on each sample spot
is necessary, as demonstrated by Hattan et al [31]. 5000
total laser shots/spot were chosen. To assess this choice,
ACTH 18-39 fragment was used at three different con-
centrations (5, 10 and 20 fmol/μl), mixed with the matrix
and spotted on each spot as internal standard. A linear
regression (data not shown) of the signal intensity against
peptide concentration (R2 = 0,985) evidences a direct cor-
relation between the concentration of the peptide and its
relative intensity in the mass spectrum [32]. The concen-
tration of 10 fmol/μl was chosen as a good compromise
between the ACTH signal intensity and the need to avoid
the signal suppression due to a high concentration of the
internal standard.
70% of proteins in the acid-fraction, 65% of proteins
obtained in the basic-fraction and 52% of proteins found
in the lipophilic fraction are common to all technical
replicates (Additional file 3: Table S1, Additional file 4:
Table S2, Additional file 5: Table S3) this indicating a
good reproducibility of the workflow. The remaining
reported identifications to the final number of 596 pro-
teins are detected in at least 3 replicates.
To analyze the reproducibility within the single
method in terms of MS profiles, we compared data
obtained by MS features. Reproducibility was also veri-
fied in the course of time to assess a potential clinical
application of this high-throughput technology. Peak in-
tensities of each peptide (associated by m/z value and re-
tention time in the column) were compared with the
same peptide in all other subfamilies creating a matrix
of Pearson correlation coefficients to estimate reproduci-
bility (Figure 3).
Data were grouped according to the chemical charac-
teristic of the resin. A good reproducibility of the overall
analytical platform is suggested by the good correlation
shown in the technical replicates (0,88 ± 0,06 for acidproteins, 0,82 ± 0,09 for basic proteins and 0,82 ± 0,11
for the liphophilic fraction).
The robotic processing of the samples has an import-
ant role in improving the reproducibility of the method.
Comparing replicates coming from the same cut-off
sample (A1 vs A1’, A2 vs A2’ etc) Pearson correlation co-
efficient is never below 85%. Comparing samples across
different cut-offs (A1 vs A2 etc), a lower correlation is
observed. This can be justified considering that cut-off is
the only manual step of the workflow.
Conclusions
The specific aim of this work was to establish an
improved method which allows the analysis of a com-
plex mixture of peptides.
The automatic platform and the SPE design, developed
to process and analyse complex plasma protein mix-
tures, results innovative and advantageous and may
eventually become a powerful tool for clinical tests in a
high throughput screening.
This multidimensional fractionation approach reduces
the analysis time (2 days are enough to process 16
plasma samples filling a 96-well plate) and the robotic
automation of sample processing, avoiding contami-
nants, promises high reproducibility (more than 85%
Pearson correlation coefficient). Moreover, this auto-
matic platform is flexible and can be freely modulated
with different fractioning elements. Since several resins
are available, the robotic platform, here described, can
be utilized with different design of SPE methods to sep-




Plasma was collected from eight healthy volunteers into
Na-EDTA-prepared collection tubes, centrifuged at 750xg
for 10 min at room temperature and stored at – 80°C.
Identical aliquots of independently pre-processed Na-
EDTA treated plasma specimens were pooled and ali-
quoted in four technical replicates. The study was
conducted upon informed consent of volunteers following
the approval by the local Ethics University-Hospital Com-
mittee in the FIRB-GENOCOR project (Protocol N.48076-
study N. 2214).
Protein depletion by cut-off
Cut-off was performed with Amicon Ultra-15 (30 KDa;
Millipore). The membrane filters were washed with 3 ml
of 10% acetonitrile (ACN) and contaminants removed
by centrifugation. 1 ml of human plasma pool was
diluted with 9 ml of 10% ACN and then loaded on fil-
ters. Cut-off units were centrifuged at 5000xg for 90 min
at 4°C. 1 ml remaining on the filter was mixed with
Figure 3 Similarity matrixes. Pearson correlation coefficients compare peptide intensities from LC-MALDI-TOF profiles. Peak intensities of each
peptide were compared with the same peptide in all other fractions. Four technical replicates for acid, basic, and lipophilic fractions were
evaluated.
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for 90 min. Protein content was quantify by BCA
method before and after cut-off. A concentration of
76 mg/ml of plasma proteins was measured in crude
plasma samples and this amount was reduced to 1 mg/
ml by cut-off depletion. The recovered protein average
was 1.3% and represent the ratio between 1 mg of MW
< 30KDa proteins and 76 mg of crude plasma. From
each sample 12.5 ml of depleted protein solution (about
16 mg) were obtained. Every fraction was splitted in six
identical aliquots and lyophilized.
Protein fractionation by pMD-LC
Four depleted plasma replicates were independently pro-
cessed in a device (Liquid handler Beckman Coulter Bio-
mek NXp) able to perform an automatic separation
using specific reservoirs for protein chemical-trapping
(patent n° WO2010/035129 A2). The resins were:
BioRad UNOsphere Q Strong Anion Exchange Support,
BioRad UNOsphere S Strong Cation Exchange Support
and Waters OASIS HLB. Slurries furnished by BioRad
and Waters were automatically re-suspended. A constant
volume of every resin suspension was transferred into a
96-well filtration plate (Captiva plate-Varian Inc). Two
wells were set for each solid state and for each sample.
Storage solutions were removed applying vacuum to the
filtration plate and recovering the liquid in a 96-well col-
lecting plate. Specific and customized binding solutions
(see Additional file 2) were prepared and each stationary
phase was washed twice with the same procedure. The
24 lyophilized plasma proteins (6 lyophilized aliquots for
each technical replicate) were suspended in 160 μl of
binding solution. Each sample was loaded on the top of
a stationary single bead packed into the 96-well plate.
The binding between resin and proteins was assured al-
ternating vacuum steps with de-pressured steps until the
solution was completely adsorbed. After adsorption,
each well was washed with binding solution to remove
non-specific proteins. Specific and customized eluting
solutions (see Additional file 2) were prepared and resins
were washed twice eluted fractions which were stored.
600 μl of 7% MeOH/ 7% tButylphosphate/ 86% Acetone
were added to the wells and precipitated proteins
(100 μg/sample determined by BCA protein concentra-
tion assay) from each well were recovered by filtration
into Captiva plate-Varian Inc.
Reduction, alkylation and digestion
After protein precipitation, all recovered samples were
robotically dissolved in 200 μl of 20 mM Ammonium
Bicarbonate pH = 8.5 and reduced at 50°C for 20 min
by the addition of 10 μl of 0,1 M Dithiothreitol (DTT).
20 μl of 200 mM Iodoacetamide were added and samples
incubated at 37°C for 30 min. Trypsin digestion wasperformed using 10 μl of 0,25 μg/μl enzyme solution
(Roche) at 37°C overnight.
Reversed phase nano-HPLC
Peptide mixtures from every well were loaded on the
auto-sampler module of an Ultimate 3000 nano-HPLC
apparatus (Dionex/LC Packings, Sunnyvale, CA, USA)
equipped with a 5 mm C18 trapping column (C18 Pep-
Map 100, 5 μm, 100 Å, 300μm id x 5 mm Dionex-LC
Packings, Sunnyvale, CA) and with a 77 μm x 150 mm
C18 analytical column (3 μm, C18 Dionex-LC Packings,
Sunnyvale, CA) equilibrated with 96% of carrier solution
A (2% ACN, 0.05% TFA) and 4% eluent solution B (80%
ACN, 0.04% TFA). A conventional two steps process
was applied: (a) 5 μl of peptide mixture was firstly
loaded, concentrated and de-salted in the trapping cart-
ridge flushed with 4% B eluent at flow rate of 20 μl/min
and then (b) runned for peptide separation by connec-
tion of trap cartridge to capillary analytical column
flushed at 300 nl/min under 30 min linear gradient from
4 to 55% of B eluent. Column effluent was monitored by
continuous 214 nm absorption recording using a 3-nL
UV flow cell. The UV cell out was automatically con-
nected to a robotic device (Probot, Dionex/LC Packings)
performing the MALDI matrix addition and eluent spot-
ting directly onto the MALDI plate. The matrix α-CHCA
solution (SIGMA) (2 mg/ml in 50% ACN,0.1% TFA),
containing also the ACTH peptide fragment (10 fmol/μl
ACTH 18-39 clip as an internal mass standard, m/z
2465,199), was added in a 1:2 v/v ratio (eluent to matrix).
The collecting of the spots started 12 min after the be-
ginning of LC run. Fractions were directly spotted onto a
MALDI plate at 12-s intervals for each spot (60 nl/frac-
tion) at a continuous flow rate of 1.923 μl/min. For each
separation run, a total of 125 fractions (spots) were
collected.
MS and MS/MS processing
MS analyses were performed on a 4800 MALDI-TOF-TOF
Analyzer (Applied Biosystems, Foster City, CA, USA),
and analytical data were processed and analyzed by a
Global Protein Server Workstation (Applied Biosys-
tems), which uses internal Mascot software (Matrix Sci-
ence, London, UK) to search peptide mass fingerprints
and to process MS/MS data. Peak selection was per-
formed in a mass range from 900 to 4000 Da. An exclu-
sion filter was applied to eliminate the internal mass
standard and sodium and potassium precursor adducts
from the peak list. The top 10 masses in each spot (12-s
chromatography time) were then selected for MS/MS
analysis. A total of 5000 laser shots were averaged from
50 sample positions. Collision gas was used to generate
the high-energy CID spectra using a source voltage of
8 kV, a collision cell voltage of 7 kV, and a second
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tively rapid due to the 200-Hz repetition rate laser and
high-speed sample stage. Searches were performed against
the IPI protein database for Homo sapiens. Database
search parameters were: mass tolerance was set at
50 ppm for precursor ion and 0.3 Da for fragment mass
value; two missed cleavages were considered for trypsin
digestion and variable modifications such as oxidation,
de-amidated, and acetyl (N-Terminal) modification
were imposed. Only the 2 top-ranked peptide matches
were taken into consideration for protein identification.
A positive identification was accepted at 97% confi-
dence level or over, meaning that the fragmentation
data quality is sufficient to ensure a >97% probability of
being assigned to the proper peptide sequence. A confi-
dence interval (CI%) was calculated by GPS Explorer
using Mascot ion score and significance, such that a CI
% value of 95% or 97%, is equivalent to a Mascot ion
score at the significance value. The individual peptide
identifications were grouped into protein identifications
and assigned a total ion CI% by GPS Explorer [33]. The
total ion score CI % is a parameter combining p-value
for MS/MS identification with MASCOT search score
and considering also the quality of MS/MS analysis by
an algorithm developed by AB SCIEX. Proteins were
considered as confidentially identified with a significant
Mascot score (>40). To eliminate false positive, a search
against IPI-random Homo sapiens was performed.
Data processing
Peak lists were obtained from nanoHPLC-MALDI-TOF
chromatograms using a mass tolerance of 0.2 amu, a mini-
mum spectral intensity of 10 and a LC-peak width ≥ 5 sec
to select the peaks. For each technical replicate of plasma
pool, three peak lists were obtained for acid, basic and lipo-
philic fractions respectively. All peak list replicates from
homogenous protein families were processed by using
Marker View version 1.2 software (Applied Biosystems/
MDS Sciex, Toronto, Canada) to perform alignments
adopting 2 min retention time and 0.2 amu mass tolerance
parameters. The obtained mass intensity profiles were
imported to Microsoft Excel files and Pearson Correlation
Coefficient of every sample was evaluated in comparison
with profiles of all the other samples. JColorGrid open
source software was then applied for color visualization of
the Pearson coefficients.
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Additional file 1: Supporting figures and tables Additional
information about results.
Additional file 2: Supporting materials and methods. Additional
information about solvents, volumes and conditions used for the
home-designed robotic platform.Additional file 3: Supporting Table 1. Proteins identified in the acid
fraction. Protein name, accession number, pI and other additional
information are reported.
Additional file 4: Supporting Table 2. Proteins identified in the basic
fraction. Protein name, accession number, pI and other additional
information are reported.
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